KahrassHBossertSSchürmannC, et al. Details of risk-benefit communication in informed consent documents for phase I/II trials. Clin Trials (this issue).
2.
KingNMPHendersonGEChurchillLR, et al. Consent forms and the therapeutic misconception: the example of gene transfer research. IRB2005; 27(1): 1–8.
3.
KimSYWilsonRDe VriesR, et al. ‘It is not guaranteed that you will benefit’: true but misleading. Clin Trials2015; 12(4): 424–429.
4.
KolaILandisJ.Can the pharmaceutical industry reduce attrition rates. Nat Rev Drug Discov2004; 3(8): 711–715.
5.
RobertsTGGoulartBHSquitieriL, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA2004; 292: 2130–2140.
6.
WaligoraMBalaMMKopernyM, et al. Risk and surrogate benefit for pediatric phase I trials in oncology: a systematic review with meta-analysis. PLoS Med2018; 15(2): e1002505.
7.
WongHHBartonCActonG, et al. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: the Cancer Research UK experience. Eur J Cancer2016; 66: 9–16.
8.
ZhangSXFergussonDKimmelmanJ.Proportion of patients in phase I oncology trials receiving treatments that are ultimately approved. J Natl Cancer Inst2020; 112: 886–892.
9.
FeustelACMacPhersonAFergussonDA, et al. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology2020; 94: e1–e14.
